# NAT2

## Overview
NAT2, or N-acetyltransferase 2, is a gene that encodes the enzyme N-acetyltransferase 2, which belongs to the family of acetyltransferases. This enzyme plays a critical role in the metabolism and detoxification of arylamine and hydrazine compounds, which are found in various drugs and carcinogens. The activity of N-acetyltransferase 2 is crucial for determining the therapeutic efficacy and toxicity of these compounds, as it influences their biotransformation in the liver, small intestine, and colon (SalazarGonzález2020Human; McDonagh2014PharmGKB). The NAT2 gene is highly polymorphic, resulting in different acetylation phenotypes—rapid, intermediate, and slow—that affect individual responses to drugs and susceptibility to certain diseases (Hein2002Molecular). These polymorphisms have significant clinical implications, as they are associated with varying risks of drug-induced toxicities and diseases such as cancer and neurological disorders (Agúndez1998Slow; HerreraRodulfo2021NAT2). Additionally, NAT2 is implicated in lipid and cholesterol metabolism, suggesting a broader role in metabolic processes (Hong2022Transcriptional).

## Structure
The NAT2 protein is involved in the metabolism of arylamines and is characterized by a specific molecular structure that influences its function. The primary structure of NAT2 consists of a sequence of amino acids that form the basis for its higher-order structures. The secondary structure includes alpha helices and beta sheets, which contribute to the protein's stability and function (Walraven2008StructureFunction).

The tertiary structure of NAT2 forms a three-dimensional conformation essential for its enzymatic activity. This structure includes a catalytic triad composed of cysteine, histidine, and aspartic acid residues, which are crucial for the enzyme's acetylation mechanism (Sim2008Arylamine). The protein's quaternary structure is characterized by its ability to form homodimers, which are important for its functional stability (Walraven2008StructureFunction).

NAT2 also undergoes post-translational modifications, such as acetylation and phosphorylation, which can affect its activity and stability (Walraven2008StructureFunction). Variants in the NAT2 gene lead to different isoforms, influencing the acetylation rates and contributing to the diversity of acetylator phenotypes observed in different populations (Walraven2008StructureFunction).

## Function
The NAT2 gene encodes the enzyme N-acetyltransferase 2, which is primarily involved in the acetylation of arylamine and hydrazine compounds. This process is crucial for the metabolism and detoxification of various drugs and carcinogens, influencing their therapeutic efficacy and toxicity (SalazarGonzález2020Human; McDonagh2014PharmGKB). NAT2 is predominantly expressed in the liver, small intestine, and colon, where it plays a significant role in the biotransformation of xenobiotics (SalazarGonzález2020Human; McDonagh2014PharmGKB).

The enzyme's activity is genotype-dependent, with different acetylation phenotypes—rapid, intermediate, and slow—resulting from single nucleotide polymorphisms (SNPs). These phenotypes affect the enzyme's catalytic activity and are linked to individual variations in drug metabolism and carcinogenesis risk (SalazarGonzález2020Human; Hein2002Molecular). NAT2's role in healthy human cells includes modifying carcinogenesis risk by catalyzing reactions that can lead to the formation of DNA adducts, as seen with carcinogens like 4-aminobiphenyl (SalazarGonzález2020Human).

NAT2 is also implicated in lipid and cholesterol metabolism, with its expression being influenced by glucose and insulin levels. This suggests a potential role in lipid biosynthesis and transport, although the exact mechanisms remain unclear (Hong2022Transcriptional).

## Clinical Significance
The NAT2 gene is clinically significant due to its polymorphisms, which influence the metabolism of various drugs and carcinogens, leading to different acetylator phenotypes: rapid, intermediate, and slow. These phenotypes are associated with varying risks of drug-induced toxicities and certain diseases. Slow acetylators are at increased risk for drug toxicity, such as isoniazid-induced hepatotoxicity during tuberculosis treatment, due to the accumulation of toxic metabolites (HerreraRodulfo2021NAT2). In cancer, NAT2 polymorphisms have been linked to different risks; for instance, rapid acetylator phenotypes are associated with an increased risk of colorectal cancer, particularly in populations with high meat intake (Gil1998Increased; Borlak2006Nacetyltransferase). Conversely, slow acetylators have been associated with a higher risk of bladder cancer (Borlak2006Nacetyltransferase).

NAT2 polymorphisms also play a role in neurological disorders. A significant association has been found between slow acetylator genotypes and early-onset Parkinson's disease, suggesting that these genotypes may be low-penetrance risk factors for the disease (Agúndez1998Slow). Additionally, non-coding variants of NAT2 have been linked to cardiometabolic disorders, with rapid acetylator phenotypes associated with elevated plasma lipid and cholesterol levels, increasing the risk of dyslipidemia and cardiovascular diseases (Hong2023Noncoding).


## References


[1. (SalazarGonzález2020Human) Raúl A. Salazar-González, Mark A. Doll, and David W. Hein. Human arylamine n-acetyltransferase 2 genotype-dependent protein expression in cryopreserved human hepatocytes. Scientific Reports, May 2020. URL: http://dx.doi.org/10.1038/s41598-020-64508-0, doi:10.1038/s41598-020-64508-0. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-020-64508-0)

[2. (McDonagh2014PharmGKB) Ellen M. McDonagh, Sotiria Boukouvala, Eleni Aklillu, David W. Hein, Russ B. Altman, and Teri E. Klein. Pharmgkb summary: very important pharmacogene information for n-acetyltransferase 2. Pharmacogenetics and Genomics, 24(8):409–425, August 2014. URL: http://dx.doi.org/10.1097/FPC.0000000000000062, doi:10.1097/fpc.0000000000000062. This article has 150 citations and is from a peer-reviewed journal.](https://doi.org/10.1097/FPC.0000000000000062)

[3. (Hein2002Molecular) David W Hein. Molecular genetics and function of nat1 and nat2: role in aromatic amine metabolism and carcinogenesis. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 506–507:65–77, September 2002. URL: http://dx.doi.org/10.1016/s0027-5107(02)00153-7, doi:10.1016/s0027-5107(02)00153-7. This article has 365 citations.](https://doi.org/10.1016/s0027-5107(02)00153-7)

[4. (Agúndez1998Slow) J.A.G. Agúndez, F. J. Jiménez-Jiménez, A. Luengo, J. A. Molina, M. Ortí-Pareja, A. Vázquez, F. Ramos, J. Duarte, F. Coria, J. M. Ladero, J. C. Alvarez-Cermeño, and J. Benítez. Slow allotypic variants of the nat2 gene and susceptibility to early-onset parkinson’s disease. Neurology, 51(6):1587–1592, December 1998. URL: http://dx.doi.org/10.1212/wnl.51.6.1587, doi:10.1212/wnl.51.6.1587. This article has 35 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1212/wnl.51.6.1587)

[5. (Sim2008Arylamine) Edith Sim, Nathan Lack, Chan-Ju Wang, Hilary Long, Isaac Westwood, Elizabeth Fullam, and Akane Kawamura. Arylamine n-acetyltransferases: structural and functional implications of polymorphisms. Toxicology, 254(3):170–183, December 2008. URL: http://dx.doi.org/10.1016/j.tox.2008.08.022, doi:10.1016/j.tox.2008.08.022. This article has 103 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.tox.2008.08.022)

[6. (Hong2023Noncoding) Kyung U. Hong, Kennedy M. Walls, and David W. Hein. Non-coding and intergenic genetic variants of human arylamine n-acetyltransferase 2 (nat2) gene are associated with differential plasma lipid and cholesterol levels and cardiometabolic disorders. Frontiers in Pharmacology, April 2023. URL: http://dx.doi.org/10.3389/fphar.2023.1091976, doi:10.3389/fphar.2023.1091976. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2023.1091976)

[7. (Hong2022Transcriptional) Kyung U Hong, Raúl A Salazar-González, Kennedy M Walls, and David W Hein. Transcriptional regulation of human arylamine n-acetyltransferase 2 gene by glucose and insulin in liver cancer cell lines. Toxicological Sciences, 190(2):158–172, September 2022. URL: http://dx.doi.org/10.1093/toxsci/kfac103, doi:10.1093/toxsci/kfac103. This article has 7 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/toxsci/kfac103)

[8. (Borlak2006Nacetyltransferase) Juergen Borlak and Stella Marie Reamon-Buettner. N-acetyltransferase 2 (nat2) gene polymorphisms in colon and lung cancer patients. BMC Medical Genetics, July 2006. URL: http://dx.doi.org/10.1186/1471-2350-7-58, doi:10.1186/1471-2350-7-58. This article has 48 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2350-7-58)

[9. (HerreraRodulfo2021NAT2) Aldo Herrera-Rodulfo, Mauricio Carrillo-Tripp, Myrna Laura Yeverino-Gutierrez, Katia Peñuelas-Urquides, Laura Adiene González-Escalante, Mario Bermúdez de León, and Beatriz Silva-Ramirez. Nat2 polymorphisms associated with the development of hepatotoxicity after first-line tuberculosis treatment in mexican patients: from genotype to molecular structure characterization. Clinica Chimica Acta, 519:153–162, August 2021. URL: http://dx.doi.org/10.1016/j.cca.2021.04.017, doi:10.1016/j.cca.2021.04.017. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cca.2021.04.017)

[10. (Gil1998Increased) J. Gil. Increased frequency of wild-type arylamine-n-acetyltransferase allele nat2*4 homozygotes in portuguese patients with colorectal cancer. Carcinogenesis, 19(1):37–41, January 1998. URL: http://dx.doi.org/10.1093/carcin/19.1.37, doi:10.1093/carcin/19.1.37. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/carcin/19.1.37)

[11. (Walraven2008StructureFunction) Jason Walraven, Yu Zang, John Trent, and David Hein. Structure/function evaluations of single nucleotide polymorphisms in human n-acetyltransferase 2. Current Drug Metabolism, 9(6):471–486, July 2008. URL: http://dx.doi.org/10.2174/138920008784892065, doi:10.2174/138920008784892065. This article has 81 citations and is from a peer-reviewed journal.](https://doi.org/10.2174/138920008784892065)